Paper Details

  1. Home
  2. Paper Details

Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial.

Author: EggerMatthias, FrösnerGert, HerzogChristian, LoáisigaArnoldo, Mayorga PérezOrlando, ZellmeyerMartina

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A single dose of a hepatitis A virosome vaccine was found to be safe and effective in protecting young children (1.5-6 years old) against hepatitis A virus (HAV) infection in a randomized, double-blind trial of 274 children in Nicaragua. The vaccine demonstrated 84.6% protective efficacy, with all infections occurring within 6 weeks of vaccination.
Paper Details　
Original Abstract of the Article :
Immunization of young children could control hepatitis A virus (HAV) infection, but the efficacy of hepatitis A vaccines in early childhood is unknown. In a randomized, double-blind trial of a single dose of a virosome-formulated, aluminum-free inactivated HAV vaccine in Nicaragua, 274 children (age...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1086/377309

データ提供：米国国立医学図書館（NLM）

Protecting Young Children from Hepatitis A

This research delves into the crucial area of childhood vaccination, specifically focusing on the efficacy of a virosome-formulated, aluminum-free inactivated hepatitis A vaccine in young children. The study, conducted in Nicaragua, involved 274 children between the ages of 1.5 and 6 years, who were randomly assigned to receive either the vaccine or a placebo. The researchers aimed to assess the vaccine's effectiveness in preventing hepatitis A infection in this vulnerable population.

Efficacy and Safety of Hepatitis A Vaccine in Young Children

The study found that the hepatitis A vaccine was highly effective in preventing infection, with a protective efficacy of 84.6% among children who were seronegative for hepatitis A. The vaccine was also found to be safe, with only rare adverse events reported. These encouraging findings suggest that vaccination can play a significant role in protecting young children from the potentially serious consequences of hepatitis A infection.

The Importance of Childhood Vaccinations

This research highlights the importance of childhood vaccinations in preventing serious diseases. The findings demonstrate the effectiveness and safety of the hepatitis A vaccine in protecting young children, underscoring the critical role that vaccination plays in safeguarding the health of future generations. Just as a sturdy camel caravan can safely navigate the treacherous desert, vaccinations provide a protective shield for children, shielding them from the dangers of preventable diseases.

Dr. Camel's Conclusion

This study underscores the importance of vaccinations in protecting children from the perils of preventable diseases. The findings highlight the effectiveness and safety of the hepatitis A vaccine, emphasizing its critical role in safeguarding the health of young children. Like a shimmering oasis in the vast desert, vaccinations offer a vital source of protection, ensuring that children can thrive and reach their full potential.

Date :
  1. Date Completed 2003-10-09
  2. Date Revised 2006-11-15
Further Info :

Pubmed ID

12934183

DOI: Digital Object Identifier

10.1086/377309

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.